Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

PureTech creates immuno-oncology firm

by Ann M. Thayer
April 17, 2017 | A version of this story appeared in Volume 95, Issue 16

PureTech Health, an R&D and venture investment firm, has launched an immuno-oncology subsidiary called Nybo Therapeutics. Building on the work of NYU School of Medicine’s George Miller, Nybo will develop monoclonal antibodies to target and neutralize newly discovered immunosuppressive mechanisms in pancreatic cancer and other solid tumors. The launch coincides with the publication of Miller’s research on the activation of the Dectin 1 immune receptor on macrophages (Nat. Med., 2017, DOI: 10.1038/nm.4314).

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.